Immunotherapy before surgery: a new hope for HPV throat cancer?
NCT ID NCT06254911
First seen Jun 25, 2026 · Last updated Aug 06, 2026 · Updated 3 times
Summary
This phase 2 trial is testing whether the immunotherapy drug atezolizumab, given before surgery, can help treat HPV-related throat cancer that can be removed. About 20 adults with stage I oropharyngeal cancer will receive two doses of atezolizumab followed by standard surgery. The study aims to see if the drug triggers an immune response against the tumor and improves outcomes like preventing recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atezolizumab (Tecentriq)
- What this could lead to
- If successful, this could show that a short course of immunotherapy before surgery helps control HPV-related throat cancer and reduces the risk of recurrence.
- What could go wrong
- This is a small, early-phase trial with only 20 participants. The study is currently suspended, and it is unknown if atezolizumab will provide meaningful benefit or cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV RELATED OROPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University Hospital Midtown
RECRUITINGAtlanta, Georgia, 30308, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.